DAWNZERA (AUTOINJECTOR)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DAWNZERA (AUTOINJECTOR) (DAWNZERA (AUTOINJECTOR)).
DAWNZERA (autoinjector) contains epinephrine, a non-selective agonist at alpha- and beta-adrenergic receptors. It causes vasoconstriction via alpha-1 receptors, bronchodilation via beta-2 receptors, and increased heart rate and contractility via beta-1 receptors, reversing anaphylactic symptoms.
| Metabolism | Epinephrine is metabolized primarily by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) to metanephrine, normetanephrine, vanillylmandelic acid (VMA), and other metabolites. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 60-70%) with minor biliary/fecal elimination (20-30%). |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults, allowing once-daily dosing; prolonged in renal impairment. |
| Protein binding | 92-95% bound primarily to albumin. |
| Volume of Distribution | Vd is approximately 0.2-0.3 L/kg, indicating distribution mainly in extracellular fluid. |
| Bioavailability | Subcutaneous: 75-80%; intramuscular: 80-85%. |
| Onset of Action | Intramuscular injection: 30-60 minutes; subcutaneous injection: 1-2 hours. |
| Duration of Action | Duration of clinical effect is 24 hours, supporting once-daily dosing. Monitor for extended effects in renal impairment. |
| Molecular Weight | 146000 |
60 mg subcutaneously once daily, administered at approximately the same time each day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). For severe renal impairment (eGFR <30 mL/min) or end-stage renal disease, use is not recommended due to lack of data. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not recommended for moderate to severe hepatic impairment (Child-Pugh B or C) due to lack of data. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy have not been established. |
| Geriatric use | No specific dose adjustment required; elderly patients may have increased sensitivity, but standard adult dosing is recommended. Monitor for adverse effects. |
| 1st trimester | Insufficient human data; based on animal studies, may cause fetal harm. Avoid unless benefit outweighs risk. |
| 2nd trimester | Insufficient human data; potential for fetal harm. Use only if clearly needed. |
| 3rd trimester | Insufficient human data; potential for fetal harm, especially during late gestation. Consider risk-benefit. |
Clinical note
Comprehensive clinical and safety monograph for DAWNZERA (AUTOINJECTOR) (DAWNZERA (AUTOINJECTOR)).
| Placental transfer | Evidence suggests placental transfer; IgG1 monoclonal antibodies cross the placenta increasingly as pregnancy progresses. |
| Breastfeeding | Unknown if excreted in human milk; caution advised due to potential for serious adverse reactions in nursing infants. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to the active substance or any excipients
| Precautions | Administration should be into the anterolateral aspect of the thigh, not into the gluteal muscle or veins. Patients with preexisting cardiovascular disease, hypertension, diabetes, hyperthyroidism, or elderly may be at increased risk of adverse effects. Use with caution in patients receiving beta-blockers or MAO inhibitors. |
| Food/Dietary | No direct food interactions. However, after recovery from severe hypoglycemia, provide oral carbohydrates (e.g., juice, glucose tablets) to prevent recurrence and replenish glycogen stores. |
Loading safety data…
| L4 - Possibly Hazardous |
| Teratogenic Risk | Pregnancy Category B. No evidence of fetal harm in animal studies; however, no adequate human studies. Risk cannot be excluded but is considered low. First trimester: Theoretical risk based on mechanism (CGRP antagonism); no human data. Second and third trimesters: No reported adverse fetal outcomes. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate during therapy. No specific fetal monitoring required; standard prenatal care advised. |
| Fertility Effects | No known impairment of fertility in animal studies. Human data lacking; theoretical risk due to CGRP inhibition in reproductive tissues. |
| Clinical Pearls |
| DAWNZERA (glucagon) autoinjector is used for severe hypoglycemia. Administer intramuscularly or subcutaneously into the outer thigh; avoid intravenous injection due to risk of thromboembolism. Onset of action is 5-20 minutes. Monitor for nausea and vomiting, which are common. Due to short half-life (8-18 minutes), follow with oral carbohydrates once patient regains consciousness. Caution in patients with pheochromocytoma or insulinoma as glucagon may stimulate catecholamine release or cause rebound hyperglycemia. |
| Patient Advice | Always keep DAWNZERA accessible and ensure family/caregivers know how to use it. · Inject into the outer thigh through clothing if necessary; avoid injecting into a vein. · After injection, turn patient on their side to prevent aspiration if vomiting occurs. · Seek emergency medical help immediately after use, even if symptoms improve. · Do not reuse the autoinjector; dispose of it properly after single use. |